MedDataX Logo

Metabolic Imaging Predict Histopathologic Response to Preop ChemoXRT for Locally Advanced Rectal CA

NCT ID: NCT00394615

Last Updated: 2010-03-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-10-31

Study Completion Date

2005-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this research study of metabolic imaging in locally advanced rectal cancer, we hope to learn whether new medical imaging technology can help predict the response of rectal cancer to preoperative chemotherapy and radiation therapy. Ultimately we hope this information will in the future help us predict which patients will benefit from more or less aggressive initial therapy for their rectal cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MRI Imaging or CT Abdomen as Standard Work-up Before Treatment Planning for Rectal Cancer?

NCT03463616

Rectal Cancer Liver Metastases
COMPLETED

Evaluation of Rectal Cancer Treatment Response Using PET/MRI

NCT02233595

Rectal Adenocarcinoma
TERMINATED

Minimal Invasive Strategies for Good and Complete Response to Chemoradiation in Rectal Cancer

NCT00939666

Locally Advanced Rectal Cancer
COMPLETED NA

Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer

NCT01460641

Rectal Cancer
COMPLETED

Tumor Response Prediction in Neoadjuvant Chemoradiation of Locally Advanced Rectal Cancer Using Metabonomics Analysis

NCT03149978

Locally Advanced Rectal Cancer
UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metabolic Imaging

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion Criteria:- You must be diagnosed with locally advanced rectal cancer and have chosen treatment with preoperative chemoradiotherapy followed by surgery, which is a standard treatment approach for this disease.

Exclusion Criteria

Exclusion Criteria:- You are ineligible for this study if you are pregnant or under the age of 18 years old.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Stanford Cancer Council

UNKNOWN

Sponsor Role collaborator

Stanford University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Stanford University School of Medicine

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Albert Koong

Role: PRINCIPAL_INVESTIGATOR

Stanford University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Stanford University School of Medicine

Stanford, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCT00394615

Identifier Type: -

Identifier Source: secondary_id

REC0001

Identifier Type: -

Identifier Source: secondary_id

REC0001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Lateral Lymph Node Dissection After Neoadjuvant Chemo-radiation in Advanced Low Rectal Cancer
NCT02614157 TERMINATED NA
Prospective Assessment of Symptoms and Quality of Life in Rectal Cancer Patients Receiving Chemo-Radiotherapy
NCT00414232 COMPLETED
PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery
NCT00004891 COMPLETED NA
Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders
NCT03941366 UNKNOWN NA
Oligometastases of the LIVer Treated With Chemotherapy With ou Without Extracranial Stereotactic Body Radiation Therapy in Patients With Colorectal Cancer
NCT03532204 WITHDRAWN NA
Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer
NCT02151019 TERMINATED PHASE1/PHASE2
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
NCT03961776 RECRUITING
Organ Preservation in Rectal Cancer: Contact X-ray Brachytherapy vs Extending the Waiting Interval and Local Excision
NCT05772923 RECRUITING NA
Clinical Relevance of Major Pathologic Regression for Locally Advanced Rectal Cancer
NCT06879197 COMPLETED
A Prospective Phase II Randomized Clinical Trial of Preoperative Chemotherapy Combined With Short-course Radiotherapy Versus Conventional Neo-adjuvant Therapy for Locally Advanced Rectal Cancer Implemented by MDT
NCT02941562 UNKNOWN PHASE2
Prediction of Response to Neoadjuvant Therapy in Rectal Cancer
NCT02439086 UNKNOWN NA
A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
NCT01064999 UNKNOWN PHASE2/PHASE3
Chemo-radiotherapy as Main Treatment Strategy for Rectal Cancer. Can we Provide a More Precise and Effective Treatment
NCT03619668 UNKNOWN
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
NCT05998122 NOT_YET_RECRUITING PHASE2
Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT02031939 ACTIVE_NOT_RECRUITING PHASE3
PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study
NCT01751516 COMPLETED
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
NCT03300544 TERMINATED PHASE1
Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
NCT07161115 NOT_YET_RECRUITING PHASE2
Neoadjuvant Therapy for Localized Rectal Adenocarcinoma
NCT04418895 WITHDRAWN PHASE2
Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer
NCT03573791 RECRUITING
Predicting RadIotherapy ReSponse of Rectal Cancer With MRI and PET
NCT02233374 COMPLETED NA
Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients
NCT01171300 ACTIVE_NOT_RECRUITING NA
Watch and Wait as Treatment for Patients With Rectal Cancer
NCT03125343 RECRUITING NA
Short-course Preoperative Chemoradiotherapy Followed by Delayed Operation for Locally Advanced Rectal Cancer
NCT01129700 COMPLETED PHASE2
Preoperative Intraarterial Chemoembolization Combined With Radiotherpy in Locally Advanced Rectal Cancer
NCT03601156 UNKNOWN NA